Furthermore, in vivo experiments demonstrated the enhanced antitumor activity of GPC-3.CAR/sIL-15 Vδ1 T cells in a xenograft tumor model, showcasing their potential for clinical application without inducing xenogeneic GVHD [33]. The gene discussed is GPC3; the disease is neoplasm.